Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Therefore, preemptive ganciclovir therapy based on early detection of CMV reactivation is widely used to prevent CMV disease. Real-time polymerase chain reaction (PCR) has been widely used for monitoring CMV reactivation as well as the antigenemia assay that detects CMV structural phosphoprotein with a molecular weight of 65,000 (pp65). We developed a real-time PCR assay system for CMV based on a double-stranded DNA-specific dye, SYBR Green I, and quantified DNA, which was extracted automatically from plasma. This real-time PCR assay and the pp65 antigenemia assay were compared in parallel with 357 blood samples obtained from 64 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Real-time PCR assay results correlated with those of the pp65 antigenemia assay ( p < 0.0001). It is noteworthy that the detection of CMV DNA by PCR preceded the first positive antigenemia by 14 days. In this study, 10 of 64 patients developed CMV disease. The antigenemia assay detected CMV reactivation earlier than the development of CMV disease only in four of 10 patients. In contrast, our real-time PCR detected CMV-DNA before the development of CMV diseases in eight of 10 patients. The real-time PCR with SYBR Green I as a detection signal is simple and readily performed, and may be a useful system for early detection of CMV reactivation after allo-HSCT.
Cytomegalovirus (CMV) continues to be a major cause of morbidity, and this occasionally leads to the death of patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (Boeckh et al. 2003) . Although ganciclovir is an effective agent for CMV infection and disease, the administration of ganciclovir causes various adverse effects, including myelosuppression and nephrotoxicity. Therefore, it is important to discriminate high-risk patients from others to avoid over-treatment. Approaches that ganciclovir is used only in high-risk patients based on monitoring of CMV reactivation are called preemptive therapies. Preemptive therapies based on the antigenemia assay which detects CMV structural phosphoprotein with molecular weight of 65,000 (pp65) as a guide for starting ganciclovir have been widely used in clinical settings (Boeckh et al. 1996; Kanda et al. 2002a, b) . However, this assay requires processing within 8 hrs of sampling, is time-consuming and suffers from a lack of standardization (Boeckh et al. 1994) . Moreover, it lacks the sensitivity needed to predict the occurrence of CMV gastroenteritis (Boeckh et al. 1996; Mori et al. 2004) , and can not be used when the leukocyte count is very low (Boeckh et al. 1997) .
The direct detection of CMV DNA based on PCR has been investigated as an alternative measure for monitoring CMV infection, but qualitative PCR may not be able to discriminate between clinically significant and insignificant reactivation in immunocompromised individuals. On the other hand, studies using quantitative PCR have been shown to be useful for detecting patients at high risk of developing CMV disease (Gor et al. 1998) . Real-time PCR, one modality of quantitative PCR, is a simple, reliable, cost-effective, and time-saving alternative strategy (Holland et al. 1991) . Many institutes have developed real-time PCR assays for monitoring CMV, and have reported encouraging results (Gault et al. 2001; Cortez et al. 2003; Li et al. 2003; Nitsche et al. 2003; Ikewaki et al. 2005) , where a dual-labeled fluorogenic hybridization probe or two singlelabeled probes have been used to monitor PCR product formation.
Recently, a novel real-time PCR technique using a fluorescence dye, SYBR Green I, which upon binding to double-stranded DNA exhibits fluorescence enhancement, has been developed. This is the simplest real-time PCR technique based on the detection of PCR products by DNAintercalating dye of SYBR Green I (Karsai et al. 2002) . The use of SYBR Green I dye provides great flexibility and reduced cost because no target-specific probes are required. We have designed a new real-time CMV PCR assay that incorporates this system (Higuchi et al. 2002) . Since cell separation from whole blood and DNA extraction could strongly affect the assay's reproducibility, we used plasma instead of peripheral blood mononuclear cells (PBMC), and a MagNA Pure automated DNA extraction instrument to automatically extract DNA from plasma. These changes made our real-time CMV PCR system much simpler than previously reported. In this study, we compared the laboratory and clinical feasibilities of this newly developed real-time CMV PCR using SYBR Green I with the existing pp65 antigenemia assay, which has been widely used as a guide for starting ganciclovir after allo-HSCT.
MATERIALS AND METHODS

Patients and samples
We tested 357 blood samples obtained from 64 consecutive patients who underwent allo-HSCT and achieved sustained engraftment in our center between April 2003 and January 2004. The blood samples for the CMV antigenemia and real-time PCR were collected once a week from day 5 -9 after transplantation until leaving our hospital. The study was approved by the National Cancer Center Institutional Review Board. All patients gave their written informed consent. The characteristics of these patients are shown in Table 1 .
Stem cell transplantation procedure
Conditioning regimens and graft-versus-host disease (GVHD) prophylaxis are shown in Table 1 . Fludarabineor cladribine-based reduced intensity regimens were used in 47 patients and conventional myeloablative regimens were used in 16. Another patient did not receive any conditioning treatment before transplantation because he had severe bone marrow suppression and bacterial infection after reinduction chemotherapy with idarubicin and cytosine arabinoside. Cyclosporine A alone, Cyclosporine A with methotrexate or tacrolimus alone, orally or intravenously was given to prevent GVHD. Ciprofloxacin, fluconazole, and sulfamethoxazole/ trimethoprim were given as prophylaxis for bacterial, fungal, and pneumocystis carinii infections. All patients were given acyclovir 750 mg/day orally from day -7 to the discontinuation of GVHD prophylaxis.
CMV antigenemia assay CMV antigenemia assay was performed by the method described previously (van der Bij et al. 1988; Gondo et al. 1994) . In brief, 150,000 peripheral blood leukocytes were cytocentrifuged on a slide and fixed with acetone within 6 hours after specimen collection. The cells were incubated with monoclonal antibody horseradish peroxidase-C7 (Teijin, Tokyo) raised against the pp65 antigen of CMV, and stained by the direct immunoperoxydase method. Under light microscopy, CMV antigenpositive cells were enumerated. The degree of antigenemia was expressed as the number of positively stained cells per 50,000 leukocytes.
Amplification and detection of viral DNA
DNA was extracted from 200 μ l of blood plasma with a MagNA Pure instrument (Roche Molecular Biochemicals, Mannheim, Germany). A MagNA Pure LC DNA Isolation Kit I was used according to the manufacturer's instructions. In the initial 42 samples, DNA was extracted manually using a QIAmp Blood mini-kit (Qiagen, Valencia, CA, USA).
We selected and designed the sequences of primers in the UL75 region of CMV. The forward and reverse primers of UL75 were 5′-CCT TGC GTG TCG TCG TAT TCT AGC-3′, and 5′-GCC TCA TCA TCA CCC AAA CGG ACA G-3′, respectively. PCR amplification was performed in a total volume of 20 μ l in the presence of 2 μl of DNA sample, 4.4 μl of PCR master mix (Takara Ex Taq R-PCR Version, Takara, Shiga), 10 pmol of each of the primers, 2 mmol of MgCl 2 , 2 μ l (1 : 15,000 dilution) of Syber Green I (SYBR Green I Nucleic Acid Gel Stains, Takara), and distilled water.
PCR was performed with a LightCycler instrument using the SYBR Green I system (Roche Diagnostics, Tokyo) under the following conditions: 95˚C for 30 sec and 35 cycles at 95˚C for 0 sec (i.e., an instrument setting of zero seconds), 57˚C for 5 sec, and 72˚C for 10 sec. Crossing points were determined by the operator dependent fit points method. Melting curve analysis was performed on all of the positive results. The melting temperature range used to determine that a specimen yielding a crossing point was a true positive was 86.5 to 87.5˚C.
Positive control and negative control
Positive PCR product DNA from a clinical sample was confirmed based on its positivity in electrophoresis and selected as the PCR standard. A direct sequence analysis was performed on this PCR product, which was confirmed to show a 100% match with GenBank data (NC_001347, similar as AD169 strain). The DNA from this sample was then subjected to molecular cloning by being inserted into the pCR4-TOPO vector (TOPO cloning kit, Invitrogen, Carlsbad, CA, USA). This plasmid was used as the CMV standard in this study. CMV was quantified using serially diluted CMV standards within the range of 1.41 × 10 to 1.41 × 10 8 copies per μ l, and the numbers of CMV copies were calculated. The specificity of the CMV PCR was assessed by testing murine CMV (Smith strain) and herpes simplex viruses (HSV) (HSV-1; KOS strain and HSV-2; Savage strain) as negative controls. The CMV PCR assay with 35 cycles was negative for these samples.
Preemptive therapy for prevention of CMV disease
The decision to start preemptive therapy was based on the detection of 10 or more positive cells per 50,000 cells by the antigenemia assay, or by the clinical diagnosis of CMV disease with apparent or infection-related symptoms. In this study, PCR results were not used in the decision-making process regarding preemptive therapy. Intravenous ganciclovir was started at 5 mg/kg/day three times per week, and was continued until the positive cell count had decreased to less than 10 per 50,000 cells. If the number of positive cells increased or CMVrelated symptoms worsened, the dose of ganciclovir was increased.
Statistical analysis and definition of CMV infection
Correlations between the number of CMV DNA and CMV antigen-positive cells were analyzed by calculating Spearman ranked correlation coefficient. Differences between two groups were assessed by the Mann-W h i t n e y 's U -t e s t . R O C ( R e c e i v e r O p e r a t i n g Characteristic) analysis was performed using ROCKIT 0.9B (Dorfman et al. 1992) . The diagnostic power of UL75-PCR was assessed by calculating of the Area under the ROC Curve (AUC). We accessed several cutoff values for positive cells, 1, 5, 10, or 50 per 50,000 examined cells, in the antigenemia assay to reflect "positive for CMV infection" on the ROC analysis. P values less than 0.05 were considered statistically significant.
RESULTS
Clinical sample amplification
Threshold cycle values of the serially diluted standard were plotted (Fig. 1A) , and showed good linearity (Fig. 1B) . The amplification results of To confirm the purity of amplification, melting curves for PCR products after amplification were examined and the presence of an extra peak was neglected (Fig. 1C) . Furthermore, amplification was confirmed by 2% agarose gel electrophoresis. Three of five samples showed a tight single 151 base-pair band in each lane, except lanes 1 and 4 (Fig. 1D) , indicating that only one product was amplified. As a reference, the calculated copy numbers and the results of the antigenemia test for these samples are shown in Fig. 1D .
Comparison of the pp65 antigenemia assay with CMV real-time PCR
A total of 357 weekly samples were obtained from 64 patients and analyzed by both real-time PCR and antigenemia assays. As a result, a total of 158 samples obtained from 40 patients were positive for antigenemia assay, 220 samples from 55 patients were positive for real-time PCR which were confirmed by electrophoresis and melting curve analysis, 113 samples were negative for both assays, and 134 were positive for both assays (Kappa = 0.53). Eighty-six samples were positive by real-time PCR and negative by the antigenemia assay, while 24 samples were negative by realtime PCR and positive by the antigenemia assay ( Table 2 ). The median number of pp65-positive cells in these 24 samples was 2 (range, 1.4 -10.3) per 50,000 leukocytes.
There was a correlation between the CMV DNA copy number and the pp65-positive cell count (R = 0.738, p < 0.0001 by the Spearman test) (Fig. 2) . Samples from patients were classified into four groups according to the results of the antigenemia assay (Fig. 3) . Group 1 (n = 199) was negative by the antigenemia assay, group 2 (n = 75) was positive at 1 to 9 cells, group 3 (n = 42) was positive at 10 to 49 cells, and group 4 (n = 41) was positive at > 50 cells. The median CMV DNA load was 0 copies/ml (range, 0 to 39,345) in group 1, 344 (2.5 log 10 ) copies/ml (0 to 172, 750) in group 2, 4,910 (3.7 log 10 ) copies/ml (0 to 141,650) in group 3, and 22,200 (4.3 log 10 ) copies/ml (2,285 to 464,750) in group 4. The CMV DNA load was significantly different in each group, as shown in Fig. 3 ( p < 0.0001 by the Kuruskal-Wallis test). The specimens negative by real-time PCR or the antigenemia test are not depicted on the graphs in Fig. 2 and 3 . 
Longitudinal analysis of the first detection of CMV DNA and CMV antigenemia cells
The CMV PCR and CMV antigenemia assays became positive simultaneously in 13 of 64 patients. The first positive PCR test preceded the first positive antigenemia by 14 days (7 to 35) in 20 patients, while the first positive antigenemia preceded the first positive PCR by 7 days in 4 patients. CMV PCR alone was positive in 18 patients, and CMV antigenemia alone was positive in 3 patients. Neither CMV PCR nor CMV antigenemia was positive in 6 patients. The median number of days for the first development of positive antigenemia and PCR results after transplantation was 34 days (12 to 141) and 20 days (12 to 97), respectively. Therefore, CMV PCR was positive significantly earlier than the CMV antigenemia assay ( p < 0.0001 by the Mann Whitney's U-test). The WBC count at the first development of positive PCR was significantly lower, with a median of 2,700/μ l (range, 100 to 27,400) than at the first positive antigenemia, with a median of 4,700/μ l (700 to 40,900, p = 0.027 by Mann Whitney's U-test). In 23 of 64 patients, preemptive ganciclovir therapy was started upon the detection of 10 or more positive cells per 50,000 cells by the antigenemia assay at a median of day 39 (range, 18 to 122) after transplantation. Despite the preemptive therapy, five of 23 patients developed CMV disease at a median of day 50 (38 to 123) after transplantation. In five of 64 patients, ganciclovir was started based on the clinical diagnosis of CMV disease with apparent or infection-related symptoms at a median of day 38 (34 to 42).
Incidence of CMV disease
Ten of the 64 patients developed CMV disease. The time pattern of PCR and antigenemia detection relative to the onset of CMV disease in the 10 patients is shown in Fig. 4 . Eight patients had CMV colitis, one had CMV retinitis (patient no. 8 in Fig. 4) , and one had CMV pneumonia (patient no. 3). In these 10 cases, cord blood transplants were performed in three cases, transplants from an HLA-mismatched unrelated donor were performed in two, transplant from an HLAmatched unrelated was performed in one, transplant from an HLA-mismatched sibling was performed in one, and transplants from an HLAidentical sibling were performed in three. The median number of days to the onset of CMV disease was 42 days after transplant (33 to 123 days). CMV reactivation was detected 3 days or more before the development of CMV disease in 8 of 10 patients by real-time PCR. However, CMV antigenemia detected CMV reactivation earlier than the development of CMV disease only in 4 of 10 patients (Fig. 4) . Five patients with CMV disease were successfully treated with ganciclovir and are currently alive, but the other five patients with CMV disease died from causes other than CMV disease. None of the patients in this series died of causes directly related to CMV disease. Fig. 3 . CMV DNA loads in plasma based on the number of CMV pp65-positive cells per 50,000 leukocytes. Samples were classified into four groups: group 1 (n = 199), negative by the antigenemia assay; group 2 (n = 75), 1 to 9 positive cells; group 3 (n = 42), 10 to 49; and group 4 (n = 41), 50 and more. The median CMV DNA levels in samples were 0 copies/ml (range, 0 to 39,345), 344 (2.5 log 10 ) copies/ml (range, 0 to 172,750), 4910 (3.7 log 10 ) copies/ ml (0 to 141,650), and 22,200 (4.3 log 10 ) copies/ml (2,285 to 464,750), respectively. The CMV DNA load was significantly different among the four groups ( p < 0.0001 by the Kuruskal-Wallis test). The box-and-whisker plots show 10th, 25th, 50th, 75th, 90th percentile values. The specimens negative by realtime PCR are not depicted. Outliers are indicated by dots.
The five deaths were caused by acute GVHD in one, disease progression in one, fungal infection in one, and bacterial infection in two. The peak CMV DNA load was significantly higher in patients with CMV disease, with a median of 82,250 copies/ml (range, 1,468 to 464,750) than in those without CMV disease, with a median of 628 copies/ml (0 to 374,150, p = 0.005, by Wilcoxon test).
Receiver Operating Characteristic (ROC) curve analysis
The ROC curves for UL75 PCR are shown in Fig. 5 , in which four cut-off points for positive antigenemia, 1, 5, 10, or 50 positive cells per 50,000, were used. The LightCycler assay was clearly better than the discrimination limit. The Area Under the ROC Curve (AUC) values were 0.8426, 0.9240, 0.9483, and 0.9564, respectively, when 1, 5, 10, and 50 positive cells was used as a cut-off point for positive antigenemia. The 95% confidence intervals were as follows: 0.7917 -0.8846, 0.8831 -0.9529, 0.9205 -0.9677, and 0.9311 -0.9736, respectively. When the cut-off point was based on 10 pp65-positive cells per 50,000 cells, there was a better correlation between the CMV antigenemia assay and CMV PCR than when the cut-off point was based on 1 pp65-positive cell. The cut-off points based on 5, 10, and 50 pp65-positive cells did not significantly differ from each other by the ROC analysis. A tentative cut-off point at copy number 1,600, as indicated by the arrow in Fig. 5 , gave a sensitivity of 87.2% and specificity of 87.9% on the ROC curve, where 10 pp65-positive cells was used as the threshold for positive antigenemia.
DISCUSSION
In our study, the CMV DNA copy number determined by real-time CMV PCR using SYBR Green I correlated with the number of pp65-positive cells, in agreement with the results of other studies using a TaqMan-based assay (Gault et al. 2001; Sanchez et al. 2001; Leruez-Ville et al. 2003; Li et al. 2003; Ikewaki et al. 2005) . ROC analysis showed that this real-time CMV PCR exhibited adequate sensitivity and specificity, using the pp65 antigenemia assay as a reference standard. Corresponding to a pp65 antigenemia value of 10 positive cells per 50,000 leukocytes, which is used as the cutoff point for initiating preemptive therapy at our institute, a CMV DNA load of 1,600 copies/ml will be proposed as a cutoff point. However, we might have to start preemptive ganciclovir therapy at a cut off value of less than 1,600 copies/ml for high-risk patients. Our real-time PCR detected CMV-DNA earlier than the antigenemia assay detected CMV reactivation in the patients with CMV disease. Our real-time PCR makes it possible to adjust timing to start preemptive therapy more accurately according to the risk for CMV disease. The risks for CMV infection and/or disease have been increasing as new strategies have been introduced in allo-HSCT, including reduced-intensity stem cell transplantation, which enables older and/or heavily pretreated patients to undergo allo-HSCT, and HLA-mismatched transplantation with T-cell depletion or anti-T-cell agents (Kanda et al. 2001a; Nakai et al. 2002) . Furthermore, Tomonari et al. (2003) suggested that the recovery of CMVspecific immunity after cord blood transplantation is delayed compared to that after BMT. Hence, in highly immunocompromised recipients, it may be advisable to set a lower cutoff point for the CMV DNA load to prevent CMV disease at the earliest stage. In this study, 47 patients underwent reduced-intensity stem cell transplantations (RIST) and 16 patients underwent conventional myeloablative stem cell transplantations (CST). The incidence of positive CMV antigenemia in the RIST group (33 of 47 patients, 70%) was higher than in the CST group (6 of 16 patients, 38%, p = 0.019). However, there was no significant difference in the incidence of positive PCR (85% and 88%) and CMV disease (17% and 13%) between the RIST group and the CST group. A higher incidence of CMV disease (10 of 64 patients, 16%) was observed and this might be attributed to our preemptive protocol consisting of a higher cutoff point and a lower initial dose of ganciclovir. It has been reported that preemptive therapy based on CMV antigenemia let to the more frequent development of CMV diseases other than pneumonitits, including gastrointestinal (GI) diseases, retinitis, and hepatitis (Boeckh et al. 1996; Kanda et al. 2001b ). Mori et al. (2004) reported that among 19 and 14 patients who developed CMV-GI disease, only 4 (21%) and 7 patients (50%), respectively, became positive for antigenemia and plasma real-time PCR before the onset of CMV-GI disease. On the other hand, our plasma real-time PCR could detect CMV-DNA before the development of devastating CMV diseases in eight of 10 patients. The immediate initiation of antiviral therapy at low CMV DNA levels may become critical for highly immunocompromised recipients.
The detection of PCR products by the DNAintercalating dye SYBR Green I system is simpler, cheaper, and probably more sensitive, since many fluorescent labels, rather than a single molecule, are incorporated into the amplified fragment (Karsai et al. 2002) . However, this technique is not sequence-specific, and consequently nonspecifically amplified PCR products and primer dimers will also be detected. Nevertheless, we performed a melting curve analysis and electrophoresis to confirm that specific PCR products were formed, and these demonstrated specific and reproducible results.
We chose plasma as an assay material since it still can be used during neutropenia (Boeckh et al. 1997 ). Plasma does not require labor-intensive processing such as isolation, counting, and adjustment of the number of peripheral blood leukocytes (PBL) before final analysis. It does not necessarily require normalization by a housekeeping gene, which is needed in real-time PCR using whole blood or PBL (Gault et al. 2001; Li et al. 2003) . Despite these advantages of plasma as an assay material, it was long considered to be a poor source for PCR-driven assays because of its low sensitivity. Since the presence of CMV is strongly associated with cell components, it is considered that samples that incorporate whole blood or PBL provide a more sensitive detection of virus than plasma (Boeckh et al. 1997) . However, recent improvements in plasma-based PCR assay have provided high sensitivity and clinical usefulness (Boeckh et al. 2004; Kalpoe et al. 2004; Schvoerer et al. 2005) . Leruez-Ville et al. (2003) reported that a smaller PCR target (74bp) could provide better quantitative results because CMV DNA of plasma might be highly fragmented. In their study, the sensitivity of the PCR test was equivalent for plasma and whole blood. Although we did not compare the sensitivities with different components of blood, we demonstrated that our plasma real-time PCR was more sensitive than CMV antigenemia, perhaps due to the use of SYBR green I, i.e., the PCR target used in this study was 151 bp, which is not small enough to explain the improved sensitivity. DNA extraction could strongly affect the assay's reproducibility (Gault et al. 2001) . Mengelle et al. (2003) demonstrated that automated extraction and quantification of DNA from whole blood, instead of separated and counted PBL, provided acceptable results. They reported that 3.4 log 10 genome copies in 200 μ l of whole blood was equivalent to a threshold value of 50 pp65-positive cells per 200,000 cells. We applied the automated extraction of DNA in plasma and demonstrated that the plasma sample had an equivalent sensitivity for preemptive therapy for CMV. Hong et al. (2004) also reported that the combination of automated plasma DNA preparation and real-time PCR detection allowed for a sensitive assay of CMV viral load after bone marrow transplantation. It is evident that the standardization of plasma separation and storage methods should improve the reproducibility of plasma CMV DNA assays, which may further support the value of automated DNA extraction.
Our real-time PCR system for the measurement of CMV DNA in plasma using automated extraction and SYBR Green I dye appears to be a practical and simple system for obtaining reliable data and early detection of CMV reactivation, particularly for the purpose of prospectively guiding preemptive therapy for CMV disease after allo-HSCT.
